Trillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of Directors

Trillium Therapeutics Inc., a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointment of pharmaceutical industry leader Michael Kamarck, Ph.D., to its Board of Directors, effective immediately.

“We are excited to welcome Dr. Kamarck to the board of directors,” said Robert L. Kirkman, M.D., Chair of Trillium Therapeutics.  “His long experience and expertise with the development and manufacturing of biologic products will be of particular value as Trillium is preparing to scale up its clinical development activities, with multiple phase 2 programs expected to start next year.”

Dr. Kamarck has significant expertise in biologics manufacturing and a breadth of management and technical experience, having served in senior leadership positions at a number of leading pharmaceutical companies during a career that spans over 25 years. He currently serves as Chief Technology Officer for Vir Biotechnology, Inc., where he manages a multi-modality technical approach to the development of treatments for serious infectious diseases such as COVID-19, influenza and hepatitis B.

“I am honored to join Trillium’s Board and look forward to contributing my knowledge in pharmaceutical research, technical operations and biologics manufacturing as the company advances towards clinical and commercial success,” said Dr. Kamarck. “This is truly an exciting time for Trillium, which is well positioned to become a leading player in the CD47 field, with a unique pipeline of two differentiated agents that are showing best-in-class potential.”

Before joining Vir, Dr. Kamarck was Senior Vice President of Global Vaccines and Biologics Manufacturing and President of Merck BioVentures where he was instrumental in establishing Merck’s global biosimilars business. Prior to Merck, Dr. Kamarck held various senior executive positions at Wyeth Pharmaceuticals, including President, Technical Operations and Product Supply, and was responsible for establishing a global biotechnology network with $3.5 billion of capital investment to manufacture several blockbuster products, including Enbrel (etanercept). He began his pharmaceutical career at Bayer serving in numerous roles in research and technical operations, including Senior Vice President of Operations for Bayer Biologicals.

Dr. Kamarck received his B.A. from Oberlin College, his Ph.D. in biochemistry from Massachusetts Institute of Technology and was a Leukemia Society Fellow at Yale University. He has authored more than 50 peer-reviewed publications and has 20 issued patents.

About Trillium Therapeutics

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

For more information visit: www.trilliumtherapeutics.com 

Investor Relations:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com
www.trilliumtherapeutics.com  

Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com